Summit Investment Advisors Inc. raised ... Headlands Technologies LLC purchased a new stake in Avidity Biosciences during the fourth quarter valued at $60,000. KBC Group NV lifted its position ...

including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 27, ...

PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced that its management team will participate in a fireside chat at the Oppenheimer Movers in Rare Disease Summit, scheduled to ...